AUSTIN, Texas, Oct. 20 /PRNewswire-FirstCall/ -- Luminex Corporation , a leading provider of multiplex technologies for bio-assays, today announced the launch of the Luminex Certified Developer Program. The Certified Developer Program brings together an elite community of licensed assay developers on Luminex’s industry leading xMAP(R) platform. Membership in the program provides benefits such as access to advanced technical training, co-branding opportunities and website exposure to the selected developers. Luminex development partners must continually meet stringent quality standards and have extensive experience and a record of success developing assays for xMAP technology in order to gain Luminex Certified Developer status. The program is expected to benefit Luminex’s extensive partner network by identifying pre-qualified xMAP assay developers with the ability to enhance the partner’s own internal development programs. Ultimately, the end-users of Luminex xMAP based solutions will also have access to a wider range of high- quality xMAP-based products.
Patrick J. Balthrop, president and chief executive officer of Luminex Corporation, commented, “With over 3,700 Luminex xMAP systems now installed worldwide, Luminex, along with our partners, intends to expand and accelerate high-quality assay development on this growing instrument base. The creation of the Luminex Certified Developer Program recognizes licensed Luminex developers who share our values and meet specific quality requirements for outsourced assay development. This certification will assist our partner network in selecting capable xMAP outsource developers and we look forward to adding more Certified Developers in the near future as the program gets fully underway.”
More information about the Luminex Certified Developer Program can be found at http://www.luminexcorp.com/developer or by sending an e-mail request to certifieddeveloper@luminexcorp.com.
About Luminex
Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company’s xMAP(R) system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company’s xMAP technology is sold worldwide and is already in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Luminex’s xMAP technology received the 2005 Clinical Diagnostics Technology of the Year Award from Frost & Sullivan. The Company was named in the 2005 Deloitte Fast 500 of fastest-growing technology companies. Further information on Luminex Corporation or xMAP can be obtained on the Internet at www.luminexcorp.com.
Statements made in this release that express Luminex’s or management’s intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “will,” “could,” “should” and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company’s actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex’s actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex’s products, the Company’s dependence on strategic partners for development, commercialization and distribution of products, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle, Luminex’s ability to scale manufacturing operations, potential shortages of components, competition, the timing of regulatory approvals and any modification of the Company’s operating plan in response to its ongoing evaluation of its business, as well as the risks discussed under the heading “Risk Factors” in Luminex’s Annual Report on Form 10-K for the year ended December 31, 2005, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Luminex Corporate Contact: Harriss T. Currie, Vice President, Finance and Chief Financial Officer Luminex Corporation 512-219-8020 hcurrie@luminexcorp.com
Luminex Corporation
CONTACT: Harriss T. Currie, Vice President, Finance and Chief FinancialOfficer of Luminex Corporation, +1-512-219-8020, or hcurrie@luminexcorp.com
